{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-029350","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.603394+00:00","generated_at":"2026-05-17T17:45:50.084487+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunocore Q2 2025: KIMMTRAK revenue $98M (+30% YoY); net loss $10.3M","bullets":["Q2 2025 net product sales of $98.0M, up 30% vs. $75.3M in Q2 2024; US sales $64.1M, Europe $33.0M.","Net loss of $10.3M ($0.20 per share) compared to net loss of $11.6M ($0.23 per share) in Q2 2024.","Cash, equivalents & marketable securities of $882.8M as of June 30, 2025; expects ~$65M in rebate payouts.","Phase 3 TEBE-AM trial (cutaneous melanoma) on track to complete enrollment in 1H 2026.","PRISM-MEL-301 (brenetafusp) dose selection expected in 2H 2025; IDMC recommended continue with no changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-029350","json":"https://secwatch.observer/filing/0001140361-25-029350.json","markdown":"https://secwatch.observer/filing/0001140361-25-029350.md","text":"https://secwatch.observer/filing/0001140361-25-029350.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036125029350/0001140361-25-029350-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036125029350/ef20053240_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:45:50.084487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}